Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Exelixis

CRISPR Therapeutics and Exelixis could be excellent long-term picks for your portfolio.

Have An Extra $1,000? Buy These 2 Biotech Stocks

Adaptimmune Therapeutics

Atreca

These three clinical-stage biotechs are all bargains after last month's marketwide downturn.

Why Adaptimmune Therapeutics, Atreca, and CRISPR Therapeutics All Tanked In March

Gilead Sciences

Johnson & Johnson

Moderna

Regeneron Pharmaceuticals

Telesis Bio Inc

Vir Biotechnology

These biotech stocks are all working on treatments that have the potential to beat the coronavirus. Don't just wait for a cure.

7 Biotech Stocks to Buy That Could Beat the Coronavirus

Crispr: Beyond Gene-Editing

Amgen

Biogen

Editas Medicine

Innoviva

Biotech stocks pulled off an impressive rally to finish 2019 strong. These names in the industry are looking to do the same in 2020.

7 Biotech Stocks to Buy and Hold in 2020

Intellia Therapeutics

The gene-editing revolution is already here, and could be a sizable boon for investors in three of the sector's top stocks.

The Top 3 Gene-Editing Stocks to Own in 2020

Amarin Corporation Plc

Amicus Therapeutics

Amicus Therapeutics, Amarin, and CRISPR Therapeutics are all way oversold.

With the Market Down, I'm Buying These 3 Stocks

The implications for the agricultural industry are massive.

Researchers Create New CRISPR Gene-Editing System for Plants

This gene-editing stock has been on fire throughout 2019. Will it stay that way going forward?

Can CRISPR Therapeutics Double Your Money in 2020?

ZUG, Switzerland and CAMBRIDGE, Mass., Feb.  26, 2020  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Doug Treco, Ph.D. to its Board of Directors at the Company’s upcoming annual general meeting to be held later this year. The Company also announced that Pablo Cagnoni, M.D., Chief Executive Officer of Rubius Therapeutics, will resign from the Board of Directors to focus on other commitments, effective immediately.

CRISPR Therapeutics Proposes Changes to the Board of Directors

These two gene-editing stocks have a lot going for them. Let's consider pipelines, partnerships, and profits to make our choice.

Better Buy:  CRISPR Therapeutics vs.  Intellia

Financial figures across the board saw significant improvements.

CRISPR Therapeutics Reports Q4 Earnings, Beats Revenue Expectations

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 1175.00% and 3.42%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics AG (CRSP) Beats Q4 Earnings and Revenue Estimates

CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. Can it continue?

CRISPR Therapeutics Shows Market Leadership With Jump To 92 RS Rating

The technique itself appears to be safe and effective in humans.

First CRISPR Gene Editing Trial in Cancer Patients Shows Promising Results

Aurora Cannabis

Aurora Cannabis and CRISPR Therapeutics have the potential to deliver million-dollar paydays for early bird investors.

2 Ultra-Risky Stocks That Could Make You Filthy Rich

What's expected to be a busy year for CRISPR stocks started off with a thud, not a bang.

Here's Why CRISPR Stocks Fell in January

EverBank Financial

NextEra Energy

Novocure

SunPower

Expand Your Portfolio with this First Profit Stock Screener

CRISPR Therapeutics AG (CRSP) closed at $51.95 in the latest trading session, marking a -0.9% move from the prior day.

CRISPR Therapeutics AG (CRSP) Stock Moves -0.9%: What You Should Know

Cue Biopharma

Vertex Pharmaceuticals

Concept-proving results for lead programs at these biotechs will send their stock prices soaring or sinking before the year's over.

3 Biotech Start-Ups That Could Soar in 2020

BioMarin Pharmaceutical

Novavax

These stocks could thump the broader markets this year.

3 Top Biotech Picks for 2020

ACADIA Pharma

Acadia Pharmaceuticals and CRISPR Therapeutics both trounced the market last year. Here's why that could continue.

2 Biotech Stocks to Watch In 2020

The gene-editing pioneer reported data from the first two patients dosed with its first drug candidate. The early results didn't disappoint.

Here's Why CRISPR Therapeutics Stock Jumped 113.2% in 2019

Alibaba

NVIDIA

Splunk

SCANS: The FAANG Of The Roaring 20s

Exponential growth is on the horizon for these companies. Investors should take note.

3 High-Growth Stocks That Can Soar

News for CRISPR Therapeutics Stock (CRSP)